Cipher Pharmaceuticals Inc.
The X-News Explorer is the ultimate source of information for investors with an affinity for the stock market who want to get a quick and convenient overview of the current news situation of a listed company. Various newswire services are available here. If a news alert is displayed, you will find company news that may be of interest to you. This service is provided by PR-Newswire.
(All figures are presented in U.S. Dollars)
Highest single-quarter revenue in the Company's history with total revenue of $13.4 million in Q2 2025Adjusted EBITDA1 in Q2 2025 was $7.6 million, an increase of 148% over Q2 2024Epuris sales volumes grew 14% in the quarter compared to Q2 2024NatrobaTM sales were $7.8 million during the quarter, a sequential increase of 16% over Q1 2025Strong cash generation with $6.0 million cash from operations in Q2 2025$15.0 million debt repayment and share repurchases of $2.1 million during Q2 2025$7.0 million debt repayment subsequent to Q2 2025MISSISSAUGA, ON, July 29, 2025 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") today announced that it will release its financial results for the second quarter of 2025 after the market close on Thursday, August 7, 2025. The Company will also hold a conference call on Friday, August 8, 2025 at 8:30am ET to discuss the results and corporate developments.
CONFERENCE CALL DETAILS
DATE:
Friday, August 8, 2025
TIME:
8:30 a.m. ET
DIAL-IN NUMBER:
416-945-7677 or 888-699-1199
REPLAY:
289-819-1450 or 888-660-6345 Code: 36094#
Expires: August 15, 2025
WEBCAST:
https://app.webinar.net/2vQrZ2AYmV5
MISSISSAUGA, ON, June 13, 2025 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") announced that it held its annual and special meeting of shareholders earlier today and that all matters put forward before shareholders for consideration and approval as set out in the Company's management information circular dated May 2, 2025 were approved by the requisite majority of votes cast at the meeting. In particular, shareholders approved the election of all director nominees, the re-approval of RSM Canada LLP as auditor of the Company and the resolution approving the unallocated shares, rights and other entitlements under the Company's share purchase plan. A total of approximately 13 million shares, representing approximately 50.9% of the total shares outstanding were represented in person or by proxy at the meeting. The detailed results of the vote for the election of directors of Cipher is set out below:
(All figures are presented in U.S. Dollars)
Adjusted EBITDA2 in Q1 2025 was $6.2 million, an increase of 73% over Q1 2024Canadian product portfolio sales volumes grew 46% in the quarter compared to Q1 2024NatrobaTM sales were $6.7 million during the quarter, a sequential increase of 3% over Q4 2024Continued strong track record of cash generation with $4.2 million cash from operations in Q1 2025$22.0 million cash balance at the end of Q1 2025$15.0 million debt repayment subsequent to Q1 2025MISSISSAUGA, ON, May 8, 2025 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") today announced its financial and operating results for the three months ended March 31, 2025.
MISSISSAUGA, ON, May 2, 2025 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") today announced that it will release its financial results for the first quarter of 2025 after the market close on Thursday, May 8, 2025. The Company will also hold a conference call on Friday, May 9, 2025 at 8:30am ET to discuss the results and corporate developments.
CONFERENCE CALL DETAILS
DATE:
Friday, May 9, 2025
TIME:
8:30 a.m. ET
DIAL-IN NUMBER:
416-945-7677 or 888-699-1199
REPLAY:
289-819-1450 or 888-660-6345 Code: 69080#
Expires: May, 16, 2025
WEBCAST:
https://app.webinar.net/9dwb3Zn3Qap
MISSISSAUGA, ON, May 1, 2025 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or "the Company") announced today that it has filed, and the Toronto Stock Exchange (the "TSX") has accepted, notice of Cipher's intention to commence a normal course issuer bid ("NCIB") for its common shares (the "Common Shares").
The TSX notice provides that Cipher may, during the 12-month period commencing May 5, 2025 and ending on May 4, 2026, purchase for cancellation under the NCIB up to 1,485,260 of its Common Shares, representing 10% of its public float of 14,852,604 Common Shares as of April 22, 2025 (a total of 25,622,940 Common Shares were issued and outstanding as of such date). The price which Cipher will pay for any Common Shares will be the market price at the time of acquisition.
MISSISSAUGA, ON, April 29, 2025 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") proudly announces the state of Illinois has updated its Preferred Drug Listing ("PDL") where Cipher's product Natroba™, for the treatment of scabies and head lice, has obtained preferred drug status on Medicaid state plans, and whereby its main competitive product Permethrin 5% has been downgraded to non-preferred status. As a result of this change, all Medicaid treatments for scabies and Permethrin 5% prescriptions in the state must first step through Natroba™ being the preferred treatment in Illinois.
(All figures are presented in U.S. Dollars)
Generated $8.3 million in cash during Q4 2024Natroba™ revenue was $12.0 million for the 5 months of fiscal 2024 since acquisitionFull year adjusted EBITDA1 of $15.7 million, an increase of 23% over fiscal 2023Cash at December 31, 2024 was $17.8 million or $0.70 per outstanding common shareEpuris revenue grew by 20% in fiscal 2024 compared to fiscal 2023Reactivation of a Normal Course Issuer Bid, which may include block purchases of the Company's common shares in accordance with TSX policiesMISSISSAUGA, ON, March 11, 2025 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") today announced that it will release its financial results for the fourth quarter and fiscal 2024 after the market close on Tuesday, March 18, 2025. The Company will also hold a conference call on Wednesday, March 19, 2025 at 8:30am ET to discuss the results and corporate developments.
CONFERENCE CALL DETAILS
DATE:
Wednesday, March 19, 2025
TIME:
8:30 a.m. ET
DIAL-IN NUMBER:
416-945-7677 or 888-699-1199
REPLAY:
289-819-1450 or 888-660-6345 Code: 49540#
Expires: March 26, 2025
WEBCAST:
https://app.webinar.net/A3drRqWpovk
MISSISSAUGA, ON, Dec. 10, 2024 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") announced today that its partner, Moberg Pharma AB ("Moberg"), issued a news release earlier today stating that MOB-015, a product for the treatment of nail fungus, did not meet the primary endpoint in the North American Phase 3 study being conducted by Moberg. The results of the North American Phase 3 study communicated by Moberg today confirm the initial indications previously informed to the market by Moberg, and accordingly announced by Cipher, on September 13, 2024.
P R O D U C T S U G G E S T I O N S
